Home > Insider Trading > Filing (0001628280-21-012477)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501697	X4 Pharmaceuticals Inc	XFOR	Biological Products, (No Disgnostic Substances) (2836)	273181608

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1738081	S. Adam Mostafa	C/O X4 Pharmaceuticals, Inc. 61 North Beacon Street, 4Th Floor Boston MA 02134	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-15	16,250	$0.00	129,002	No	4	A	Direct
Common Stock	Disposition	2021-06-15	5,417	$7.84	123,585	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 15, 2021. One third of the shares will vest on June 15, 2022, and one third of the shares will vest on June 15, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.74 to $8.20, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents unvested restricted stock units.